FDA Advisory Committee Splits On Combivent “Essential Use” Designation
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-Allergy Drugs Committee votes 5-5, with two abstentions, that Boehringer Ingelheim’s Combivent should retain “essential use” designation. King’s Intal gets committee nod for essential use by slim margin. Committee votes to remove essential use designation for five CFC metered-dose inhalers drugs.
You may also be interested in...
Limited ANDA Overlap With Ivax Creates Strong Position For Part D Benefit, Teva Says
There is "substantial non-overlap" between Teva's and Ivax' abbreviated new drug applications, Teva North America CEO George Barrett said
Limited ANDA Overlap With Ivax Creates Strong Position For Part D Benefit, Teva Says
There is "substantial non-overlap" between Teva's and Ivax' abbreviated new drug applications, Teva North America CEO George Barrett said
Advisory Committee To Decide If Azmacort, Alupent, Intal Remain "Essential" Drugs
FDA's Pulmonary–Allergy Drugs Advisory Committee will be asked at July 14 meeting whether these and other asthma products provide an otherwise unavailable important public health benefit. Drugs using chlorofluorocarbon propellants could be delisted from essential use category if closely related non-CFC alternatives exist, even though they are not the same moiety, FDA suggests.